Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro.
Enteroviral persistence has been implicated in the pathogenesis of several chronic human diseases, including dilated cardiomyopathy, insulin-dependent diabetes mellitus, and chronic inflammatory myopathy. However, these viruses are considered highly cytolytic, and it is unclear what mechanisms might permit their long-term survival. Here, we describe the generation of a recombinant coxsackievirus B3 (CVB3) expressing the enhanced green fluorescent protein (eGFP), which we used to mark and track infected cells in vitro. Following exposure of quiescent tissue culture cells to either wild-type CVB3 or eGFP-CVB3, virus production was very limited but increased dramatically after cells were permitted to divide. Studies with cell cycle inhibitors revealed that cells arrested at the G(1) or G(1)/S phase could express high levels of viral polyprotein and produced abundant infectious virus. In contrast, both protein expression and virus yield were markedly reduced in quiescent cells (i.e., cells in G(0)) and in cells blocked at the G(2)/M phase. Following infection with eGFP-CVB3, quiescent cells retained viral RNA for several days in the absence of infectious virus production. Furthermore, RNA extracted from nonproductive quiescent cells was infectious when transfected into dividing cells, indicating that CVB3 appears to be capable of establishing a latent infection in G(0) cells, at least in tissue culture. Finally, wounding of infected quiescent cells resulted in viral protein expression limited to cells in and adjacent to the lesion. We suggest that (i) cell cycle status determines the distribution of CVB3 during acute infection and (ii) the persistence of CVB3 in vivo may rely on infection of quiescent (G(0)) cells incapable of supporting viral replication; a subsequent change in the cell cycle status may lead to virus reactivation, triggering chronic viral and/or immune-mediated pathology in the host.
Feuer
Ralph
R
Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA.
Mena
Ignacio
I
Pagarigan
Robb
R
Slifka
Mark K
MK
Whitton
J Lindsay
JL
D002453:Cell Cycle / Q000502:physiology*; D003470:Culture Media; D029822:Enterovirus B, Human / Q000235:genetics / Q000254:growth & development* / Q000472:pathogenicity*; D049452:Green Fluorescent Proteins; D006367:HeLa Cells / Q000166:cytology; D006801:Humans; D008164:Luminescent Proteins / Q000235:genetics / Q000378:metabolism; D011995:Recombination, Genetic; D014775:Virus Activation; D017735:Virus Latency; D014779:Virus Replication
D003470:Culture Media; D008164:Luminescent Proteins; D049452:Green Fluorescent Proteins